Klaviyo Director Sold Over 9,000 Shares: Investor Insight
When a Klaviyo director sold over 9,000 shares, it sparked questions about timing, risk, and company confidence. This...
Fund reallocation matters when priorities shift. This intro explains why adjusting allocations supports your financial plan.
21,681 articlesWhen a Klaviyo director sold over 9,000 shares, it sparked questions about timing, risk, and company confidence. This...
When Warren Buffett stepped aside, Greg Abel took the wheel at Berkshire Hathaway. This article breaks down his first...
A director quietly sold a notable stake in American Superconductor, prompting questions about what it signals for inv...
When kevin warsh's inflation testimony landed, traders priced an 86% chance of a Fed rate hold. This article breaks d...
Greycroft increased its Sportradar stake in a year where the stock fell sharply, illustrating how big investors respo...
When Space Force makes obvious moves to pause launches from Boeing and Lockheed's space venture, investors face a tes...
When a tech titan speaks, markets listen. This article breaks down NVIDIA's latest signals from the GTC AI conference...
American Express is scrapping its long-standing unit-by-unit bonus race. The company now ties executive pay to overal...
When a founder makes a bold move after a price drop, investors sit up and take notice. This article unpacks what a pu...
Investors are eyeing Atour's Q1 2026 updates. This guide explains how to read the atour (atat) 2026 earnings narrativ...
Markets braces for resolution as headlines renew talk of an imminent Iran deal. This report tracks how investors pric...
A late-stage setback for Jazz Pharmaceuticals' lung cancer drug Zepzelca rattled investors, but the larger story may ...